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Abstract
Background: Differential methylation of the two alleles is a hallmark of imprinted genes.
Correspondingly, loss of DNA methyltransferase function results in aberrant imprinting and
abnormal post-fertilization development. In the mouse, mutations of the oocyte-specific isoform of
the DNA methyltransferase Dnmt1 (Dnmt1o) and of the methyltransferase-like Dnmt3L gene
result in specific failures of imprint establishment or maintenance, at multiple loci. We have
previously shown in humans that an analogous inherited failure to establish imprinting at multiple
loci in the female germline underlies a rare phenotype of recurrent hydatidiform mole.
Results: We have identified a human homologue of the murine Dnmt1o and assessed its pattern
of expression. Human DNMT1o mRNA is detectable in mature oocytes and early fertilized
embryos but not in any somatic tissues analysed. The somatic isoform of DNMT1 mRNA, in
contrast, is not detectable in human oocytes. In the previously-described family with multi-locus
imprinting failure, mutation of DNMT1o and of the other known members of this gene family has
been excluded.
Conclusions: Mutation of the known DNMT genes does not underlie familial hydatidiform mole,
at least in the family under study. This suggests that trans-acting factors other than the known
methyltransferases are required for imprint establishment in humans, a concept that has indirect
support from recent biochemical studies of DNMT3L.
Background
Genomic imprinting refers to the process whereby in
mammals certain genes are differentially expressed from
the paternal and maternal alleles. The primary imprint
"mark" that distinguishes maternal and paternal alleles
has to be placed on a gene during gametogenesis, the only
time at which the two alleles are in different cellular envi-
ronments. This mark could be in the form of methylation
or perhaps some other epigenetic modification to the
chromatin. The sequelae of the primary imprint, however,
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pend not just on the presence of this initial gametic
"mark", but also on the postzygotic interpretation of such
primary imprints, into the form of stable epigenetic differ-
ences between the two alleles.
The expression of a normal pattern of genomic imprinting
in the mouse embryo depends on the activity of the DNA
methyltransferase Dnmt1 [1]. Consequently, Dnmt1 defi-
ciency is an embryonic lethal [2]. Because Dnmt1 shows
preferential activity against hemimethylated DNA, it has
been proposed to be involved primarily in maintaining
methylation patterns through rounds of DNA replication,
rather than establishing them de novo. However, the fact
that Dnmt1 predominates at all stages of embryogenesis
suggests that it may be involved in de novo methylation as
well as maintenance [3,4].
A notable feature of Dnmt1 is the existence of gamete-spe-
cific isoforms, a finding that points to unique develop-
mental roles, distinct from those of the ubiquitous
somatic isoform. These different isoforms are generated
by alternative Dnmt1 promoter usage. The mouse oocyte-
specific transcripts initiate in exon 1o, 6 kb upstream of
the major somatic exon 1 [5]. Exon 1o lacks an in-frame
initiation codon, so that translation of this mRNA species
initiates from a downstream ATG in exon 4, yielding the
N-truncated Dnmt1o protein. This isoform is enzymati-
cally active and can rescue a Dnmt1 null mutation when
expressed in ES cells [6].
During late oogenesis, accumulating Dnmt1o becomes
excluded from the nucleus and at fertilization is seques-
tered in the subcortical cytoplasm. It only re-enters the nu-
cleus transiently at the 8-cell stage, shortly thereafter to be
re-excluded. This translocation (dictated by specific nucle-
ar and cytoplasmic localization signals) [7] suggests that
Dnmt1o may provide a temporally-critical function early
in embryogenesis; this might involve the replication,
propagation or interpretation of early methylation pat-
terns at selected loci (in particular imprinted genes) that
are then subsequently able to escape the global genomic
demethylation that occurs in later preimplantation devel-
opment [8]. This prediction was strikingly confirmed by
deleting the Dnmt1o promoter in the mouse germline [9].
Homozygous mutants show a maternal-effect phenotype
in which Dnmt1o fails to accumulate during oogenesis,
and their resulting offspring die during late gestation. This
is associated with a partial (50%) failure to appropriately
maintain the methylation of imprinted alleles post-zygot-
ically. However, there is no defect either of global methyl-
ation levels in embryos, or of the establishment of
methylation in the oocyte. The latter fact implies that oth-
er methylases may be responsible for setting the primary
methylation imprint "mark" in the oocyte. In contrast, the
accumulated Dnmt1o appears to be required post-zygoti-
cally, for the maintenance of imprints during one critical
S phase (8–16 cell stage) of preimplantation develop-
ment.
By sequence homology criteria, five members of the mam-
malian Dnmt family have been recognized [10]. One of
these, Dnmt3L, lacks sequence motifs involved in methyl-
transferase catalytic activity, but has an interesting expres-
sion pattern restricted to testis and ovary [11]. Its
importance in establishing imprints was again demon-
strated by mouse knockouts, in which homozygous
mothers produce abnormal conceptuses that lack correct
methylation imprints on the maternal allele [12,13].
Several inherited human disorders can result from failure
to establish correct genomic imprinting within individual
imprinted chromosomal domains. At the Prader-Willi/
Angelman syndrome locus (15q11-q13), the exact nature
of the responsible mutations has been identified; a small
imprinting centre (IC) defined by these mutations con-
trols the setting of imprints across a ~2 Mb genomic re-
gion [14]. However, comparable cis-acting mutations at
other imprinted loci are implicated in Beckwith syndrome
[15], transient neonatal diabetes [16] and pseudohy-
poparathyroidism type Ib [17]. In contrast to these disor-
ders, we have recently defined a clinical situation in which
there is a failure to establish methylation imprints at mul-
tiple loci [18]. This failure appears selective for loci that
are normally maternally imprinted (the majority of all im-
printed genes). The condition manifests as a recurrent
form of hydatidiform mole, clinically indistinguishable
from the more common, sporadic androgenetic mole, but
in which a full haploid chromosome complement from
both parents is present. The inheritance of this condition
(familial biparental hydatidiform mole, FBHM) suggests
that affected women are homozygous for a recessive mu-
tation in a trans-acting factor required for imprint estab-
lishment during oogenesis.
The demonstration of the existence of trans-acting im-
printing control genes in both humans and mouse raises
the issue of the extent to which the components required
for correct imprinting are conserved in both species. We
have addressed two questions in the present report; (i) we
have investigated the existence of a human oocyte-specific
DNMT1 isoform and (ii) we have examined the possibili-
ty that mutation of one of the human DNMT family mem-
bers could underlie FBHM.
Results
Female germline-specific DNMT1 isoform
We first investigated the existence of a human equivalent
of the mouse oocyte-specific Dnmt1o isoform. EST data-
base entries matching the 5' part of the DNMT1 mRNAPage 2 of 8
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ends were then compared to the DNMT1 locus genomic
sequence. This analysis indicated the existence of possible
novel first exons at -6 kb (EST BE537788) and -37 kb
(ESTs BE902068, AW977685, AI798069) relative to the
known somatic exon 1.
To test for oocyte-specific expression, two preparations of
cDNA from single mature oocytes were amplified using
primers specific for the somatic DNMT1, for EST
BE537788, and for EST AI798069. Strong PCR products
were obtained from both oocyte cDNAs, only with the
BE537788 primers. These oocyte cDNAs were negative for
somatic DNMT1 and for the AI798069 EST. The
BE537788 primers also yielded a weak product in fetal
ovary cDNA (which was also positive for the somatic
DNMT1, and very weakly for AI798069). In contrast, no
expression of the BE537788 EST could be detected in a
range of somatic fetal tissues, although widespread
DNMT1 expression was detected in these tissues using
primers in exons 4 and 5 or exons 36–39. The BE537788
EST therefore appeared to represent a DNMT1 isoform ex-
pressed preferentially in human oocytes, and scarce or ab-
sent in other tissues. We therefore refer to transcripts
containing the novel exon in BE537788 (Figure 1b) as
DNMT1o.
As noted above, this novel exon (nt 145549–145765 of
AC011511) lies, similarly to the murine Dnmt1o exon, 6
kb upstream of the somatic exon 1, and splices onto exon
2. Despite this, there is little or no sequence similarity be-
tween the human and murine sequences in the region of
the oocyte-specific exon (Figure 1a). This may not be en-
tirely unexpected, given that in both species the predicted
translation initiation site for the oocyte-specific mRNA is
farther downstream in exon 4. This presumably results in
a lack of evolutionary pressure for maintaining the se-
quence of the oocyte-specific exon.
We next attempted to assess the time course of DNMT1o
in human oocyte development. A panel of cDNAs repre-
senting stages from primordial oocyte through to early
blastocyst was examined (Figure 1c). DNMT1o was con-
sistently detectable in mature oocytes, and also in some
early embryo samples (2- and 4-cell stage). Somatic
DNMT1 was absent from the oocyte cDNAs, though de-
tected in one 4-cell and one blastocyst stage embryo.
DNMTs as candidate genes in inherited hydatidiform mole
As described in the Introduction, DNMT1o and DNMT3L
are good candidates for involvement in FBHM. In one
family with this rare disorder, we have demonstrated a ge-
nome-wide failure to establish methylation imprints in
the female germline [18]. We therefore performed muta-
tion analysis of the index case in this family, who has had
six successive molar pregnancies and is the product of a
consanguineous mating.
A DNMT1o PCR product of normal sequence was ob-
tained from this patient, who was also heterozygous for
the nearby microsatellite markers D19S916 and
D19S413. Since the causative mutation in this family is
expected to be homozygous by descent, this makes in-
volvement of DNMT1 unlikely.
We next deduced the human DNMT3L gene structure [11]
from the genomic sequence AP001753 and designed
primers for PCR-amplification of each exon. No mutation
in the index FBHM patient was found on sequencing all
11 coding exons. One heterozygous A to G substitution in
exon 9 was found in the patient, predicting the amino-
acid change R278G. R278 is conserved in all other
DNMT3 family members [11], but despite this, we found
that R278G was a common polymorphic variant; a diag-
nostic SmaI digest demonstrated the presence of this
change on 8 out of 42 alleles. Lack of identity by descent
in the FBHM family was confirmed for both affected indi-
viduals for whom DNA was available, using the closely
flanking markers D21S1411 and D21S1912. Together
with the heterozygous intragenic polymorphism, this ef-
fectively rules out the possibility of an undetected
DNMT3L mutation (assuming homozygosity by descent).
It has been suggested that Dnmt3L is involved in imprint
establishment by interacting with Dnmt3b and/or
Dnmt3a [13]. The cognate human DNMT3A and
DNMT3B genes therefore required assessment. Markers
adjacent to DNMT3A (D2S171, D2S174) were hetero-
zygous in the index case in our FBHM family, making the
involvement of this gene highly unlikely. Around
DNMT3B, however, there appeared to be a region of prob-
able homozygosity by descent in both affected individu-
als. We therefore sequenced this gene in the index case.
No pathogenic mutation was identified in exons 1b-23.
(We were unable to amplify the very GC-rich exon 1a.)
Several previously reported polymorphic variants from
the reference genomic sequence (AL035071) were noted.
Three new variants were also noted; homozygous changes
C→T at nt55630 (IVS12 +30) and G→A at nt65452
(IVS21 +139), and more importantly a heterozygous si-
lent change in exon 18 (nt60758). The latter suggested
that the DNMT3B genomic region was not in fact ho-
mozygous by descent in the index case. We confirmed this
by identifying and typing a new polymorphic GT repeat at
nt21057-21106. The index case in the FBHM family was
heterozygous, which since this marker lies only 1.3 kb up-
stream of exon 1a, effectively eliminates the possibility of
homozygosity for an exon 1a mutation.Page 3 of 8
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a. PIP (percentage identity plot) diagram for human and murine DNMT1. The horizontal axis represents the human 
genomic sequence and has been annotated to show the position of the novel exon 1o, which unlike the previously recognized 
DNMT1 exons, shows no sequence conservation relative to mouse. Tall black rectangles indicate the positions of the known 
human DNMT1 exons. Low grey and white rectangles indicate regions with CpG-island like features (CpG/GpC respectively ≥ 
0.75 and ≥ 0.60). b. Alternative first exon (1o) of human DNMT1. The exon is in upper case. Underlining indicates the 
PCR primers used for genomic sequence analysis (flanking) and double underlining for RT-PCR analysis of oocyte material. c. 
Detection of DNMT1 expression in cDNA from human oocytes and embryos. The panel labelled DNMT1o shows 
PCR reactions using the upstream primer indicated in panel b, unique to the novel isoform of human DNMT1. In the DNMT1s 
panel, an upstream primer in the previously defined exon 1 was used. The ZP3 panel shows control reactions that detect the 
mRNA for zona pellucida protein ZP3, which is expressed at all stages of oogenesis. Lanes 1–2, primordial follicles (P); 3, mix 
of primordial and early primary; 4, mix of early primary and primary (1°); 5, primary; 6, secondary (2°); 7–9, ovulated oocytes; 
10, 2-cell embryos (2); 11–12, 4-cell embryos (4); 13–16, blastocysts; 17, negative control (0).Page 4 of 8
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unknown function. Six markers spanning the 6 cM inter-
val D10S1864-D10S203, around DNMT2, were all ho-
mozygous in the FBHM index case, suggesting
homozygosity by descent for this region. The human
DNMT2 structure was again deduced (from genomic se-
quence of AL133415) and all eleven exons were se-
quenced. Four polymorphic substitutions were identified
(Table 1), only one of which predicts an amino-acid
change (H101Y). No changes specific to the FBHM patient
were identified.
Discussion
In the mouse, paternally imprinted genes are required for
correct development of extraembryonic membranes and
trophoblast [20]. In contrast, the lack of maternally im-
printed genes, in androgenetic conceptions, result in poor
embryo development, while trophoblast develops com-
paratively well [21]. In humans, the phenotype resulting
from androgenesis is distinctive, comprising a complete
hydatidiform mole (CHM) in which embryo develop-
ment is poor or absent while abnormal trophoblast tissue
proliferates [22]. We have, further, recently shown that
rare cases of CHM that are biparental may arise through
failure of the maternal genome to acquire imprints during
oogenesis. This failure affects multiple imprinted loci, and
therefore presumably reflects deficiency of an oocyte-spe-
cific trans-acting factor required for imprint establishment
[18]. Based on recent studies of mouse knockouts, the
DNMT3L, DNMT3A, DNMT3B and DNMT1 (DNMT1o
isoform) loci all represent candidates for involvement in
human trans-acting imprinting defects [9,12,13]. Reces-
sive mutations of the human DNMT3B gene, however, are
known to cause ICF syndrome (MIM 242860) [23–25].
This disorder, in which juxta-centromeric repeat methyla-
tion is abnormal, bears no phenotypic resemblance to FB-
HM, and DNMT3B might therefore be dismissed as a
FBHM candidate. However, all ICF syndrome patients
have mutations of specific residues in the C-terminal cat-
alytic domain, with no patients homozygous either for
clearly null mutations (this being presumed lethal; [26] or
for missense mutations in the non-catalytic regions of the
protein. Thus it still remained possible that different mu-
tations altering DNMT3B interaction with chromatin or
other proteins might underlie FBHM.
Our present results, though, rule out known members of
the DNA methyltransferase-like group as the gene mutat-
ed in our FBHM family. Although based only on one fam-
ily, this result is significant, because it implies that other
oocyte-specific components participate in establishing the
epigenetic modifications needed for correct imprinting in
the human female germline. Recent studies of DNMT3L
are interesting in this regard. These studies show that in
vitro, DNMT3L can mediate transcriptional repression by
recruiting histone deacetylase via the conserved PHD
(plant homeodomain) motif of DNMT3L [27,28]. It re-
mains to be seen, though, whether such interactions are
relevant to the in vivo mechanism through which Dnmt3L
mediates maternal imprinting in the germline. Indeed,
other recent work indicates the possibility of a wider role
for DNMT3L as a stimulatory cofactor for de novo methyl-
ation by DNMT3A [29].
Finally, FBHM may, additionally, be a genetically hetero-
geneous condition. Two previously described families ap-
pear to map to a locus on chromosome 19q [30], whereas
linkage to this region has been previously excluded in our
family [18]. It is currently unknown whether a defect of
methylation of imprinted genes is present in molar tissue
of 19q-linked families. It therefore also remains possible
that there is further genetic heterogeneity, and that DNMT
mutations could result in a FBHM phenotype in other
families.
Conclusions
A human oocyte-specific form of the DNMT1 mRNA has
been identified, and may correspond to murine Dnmt1o.
Mutation of known DNA methyltransferase genes does
not underlie a trans-acting imprinting defect that mani-
fests as familial biparental hydatidiform mole. This sug-
gests the existence of other factors required for specifying
imprinting in the female germline.
Table 1: Coding region polymorphisms, defined during DNMT mutation screening. Nucleotide numbering refers to cDNA sequence 
AF012128 (DNMT2) or AF194032 (DNMT3L).
Gene nt change (cDNA) Exon Effect Frequency
DNMT2 G175→A 2 silent A = 6, G = 4
DNMT2 T217→C 3 silent T = 8, C = 2
DNMT2 C308→T 4 His101→Tyr T = 6, C = 4
DNMT2 G556→T 8 silent G = 8, T = 2
DNMT3L A1316→G 9 Arg278→Gly A = 34, G = 8
Frequencies were those observed among 10 alleles sequenced (DNMT2) or assessed by diagnostic restriction digest (DNMT3L).Page 5 of 8
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RT-PCR analysis of DNMT1 expression in oocytes
Detailed descriptions of the harvesting of human oocyte
material and cDNA preparation will be published else-
where (Huntriss et al., in preparation). Briefly, follicle
samples were obtained from an ovarian cortex biopsy do-
nated for research (22 year-old woman), and were meas-
ured and staged microscopically. Metaphase II oocytes
and preimplantation embryos were surplus to clinical re-
quirements under IVF or ICSI procedures. All samples
were obtained with informed consent under ethically ap-
proved protocols including a licence from the Human Fer-
tilisation and Embryo Authority (HFEA). RNA was
prepared by binding of lysates to oligo(dT)25 magnetic
beads (Dynal Biotech, Oslo, Norway), according to the
manufacturer's protocols. cDNA was synthesized using a
SMART™ protocol (Clontech, Palo Alto, U.S.A.) and pre-
amplified using PCR primers matching the SMART IV and
CDS III/3' sequences in the cDNA (SMART cDNA library
construction kit).
Individual PCR reactions were then performed on this cD-
NA, using the following cycling conditions: 5 min at 94°C
followed by 9 cycles of 94°C for 30 s, 70°C (reduced by
1°C each cycle) for 30 s, 72°C for 60 s and then 32 cycles
of 94°C for 30 s, 61°C for 30 s, 72°C for 60 s. The
DNMT1s-specific upstream primer (exon 1) was dTCT-
GCTGAAGCCTCCGAGATG and the DNMT1o-specific
primer (Figure 1b) was dCTGGATGAAAGACAGCTGGAT-
TC.
The common downstream primer (exon 5) was dCCT-
GGTGCTTTTCCTTGTAATC.
Mutation analysis
Mutation analysis was performed by direct cycle-sequenc-
ing of PCR products, using either 33P-ddNTP labelling
(Amersham Biosciences, Uppsala, Sweden) or BigDye flu-
orescent terminators and an ABI377 sequencer (Applied
Biosystems, Foster City, U.S.A.).
Primers for amplification and sequencing of DNMT3L:
Exon 1: dGCTGACGGCTTTCTCACATCT dTGGGATCAG-
CATCCTAAGTGA
Exon 2: dTTTGGAAAACGAATTGTGATGC dTTGTCTGGT-
GTGGGCCAGTAT
Exons 3–4: dTTTGACAGCACTGGGAAAACA dGAAT-
GAGTAGCTGAAAGGATGG
Exon 5: dCCAAAACAAGGCTCAATCAGG dGTAAGTCAG-
GGCCTGCTGCT
Exon 6: dGGCACAATGTCCTGTTTTGGT dTCCATGTGT-
GTCTTTGGGACA
Exon 7: dACAATCCACGCTCACCCTCT dGTCTGAGAGT-
TCACGGCGGTA
Exon 8: dACTGCTGCTGCCTCTCAGTG dGACAGGCT-
GCCAGAACTGAA
Exon 9: dCTCTCAAGCCCCAGTTTCCTT dACTGAGCTC-
CACCAGAAAAGC
Exon 10: dTTACCGTCCAGGTCCCCTGA dATGTTC-
CCCTTGACCCTGAAC
Exon 11: dCTGCGCTTGCTCACAACCTT dACGTGAG-
GAAAGTTGCCTTTG
Exon 4 sequencing primer: dGGAT-
GACACAAGCCAGCCT
Primers for amplification and sequencing of DNMT3B:
For exon 1b, PCR primers were dGACAGGCCAGCAGAC-
CAATG and dCAGGATGCATTCTTAGGGTGAT. Other
PCR primers were as previously described [25]http://
humgen.med.uu.nl/research/ICF/default.html. To ampli-
fy a polymorphic (GT)n sequence upstream of exon 1a,
dTCACCTGGTAAGAGATAC and dTGCCCAGATCTTT-
GCAGG were used.
Primers for amplification and sequencing of DNMT2 (for
each exon, the first two primers given were used for PCR,
others for sequencing):
Exon 1: dGAGACGGGGGAACTGAAACG dGAGAAG-
GGAGTCAGCGTCTG dGCAGGCCTAGCTCCGGGGCT
Exon 2: dCCACTGACAGTCTGAGATGAGG dCAATCA-
CATTTCCCTTGCTACA dTCTATAATGAACTTAAGGAC
Exon 3: dACCAAAGTTGATTTGACAAGCA dGCAT-
GAAAATGGACCAATACAA dTCCCCATTCTATCCATGTTT
Exon 4: dTTTTTGTGAGGACCAACTTATTTTT dTTCCA-
GACCTGGAGTTTCAAAT dAGTGATTTGACATCTTTT-
TATC
Exon 5: dTCTCCAGCCTTATAAAATTCCA dTGTCAGAAT-
GTATGCACTGGTTT dCTTAGTAATGAGATATTTAGAAT
Exon 6: dCCTGGGCAACAGAGTGAGACT dAAGCCAT-
TCTGCTTATCGAATC dAATAAGAACTGCCTTTCCAAGPage 6 of 8
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dAACAGCCTTGAAGATGGACCTA dTGCTGTTTAACTT-
GGTGCTAA
Exon 8: dTTTAATGGCAACCCCATAAAG dGGCAAT-
TAAGGGAAAATACCTCA dCGTAATGTTGACTGGA-
CATTG dTGGATACAGGATCAATAGATC
Exon 9: dTTCAGAAGGATGTAACTGTGTAGATTG dCAT-
GGCCAGTTGAATGCATAA dACACATACATCAGGTGCT-
GCA
Exon 10: dCTTTGCCACTGTGTGTTACAGC dGCAAGTC-
CTAGACACACAAGTCC dAATCTAGTTGCACATTACTT
Exon 11: dTGGCTCCAAATTCTCTTTTGTT dTGCCTGT-
TATGACACTTCACAAG dAAGGATACATCCTTTCATCTC
dTACTCATGTAGACACTAAAGC
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